- Conditions
- Hypoxic-Ischemic Encephalopathy
- Interventions
- RLS-0071, Placebo
- Drug
- Lead sponsor
- ReAlta Life Sciences, Inc.
- Industry
- Eligibility
- Up to 10 Hours
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 15
- States / cities
- Little Rock, Arkansas • Orange, California • San Diego, California + 11 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 385–408
of 1,585
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Stable Coronary Artery Disease
- Interventions
- Selatogrel, Placebo
- Drug
- Lead sponsor
- Viatris Innovation GmbH
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 346 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018
- U.S. locations
- 7
- States / cities
- Jacksonville, Florida • Tampa, Florida • Chicago, Illinois + 4 more
- Conditions
- Hypercarbia
- Interventions
- Ketamine, Placebo
- Drug
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years to 64 Years · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 2014
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Infertility, Infertility, Female, Oocyte Retrieval, Postoperative Pain, Embryo Transfer
- Interventions
- Ketorolac (Toradol), Placebo (saline)
- Drug · Other
- Lead sponsor
- Shady Grove Fertility Reproductive Science Center
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 2
- States / cities
- Rockville, Maryland • Fairfax, Virginia
- Conditions
- Migraine, Facial Pain or Pressure, Headache
- Interventions
- Topical solution of 4% lidocaine, Saline 0.9%
- Drug
- Lead sponsor
- Association of Migraine Disorders
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Springfield, Massachusetts
- Conditions
- Obesity
- Interventions
- Active transcranial direct current stimulation (tDCS), Hypocaloric diet, Sham transcranial direct current stimulation (tDCS)
- Device · Other
- Lead sponsor
- University of Sao Paulo
- Other
- Eligibility
- 20 Years to 40 Years · Female only
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Recurrent Pericarditis
- Interventions
- RPH-104, Placebo
- Biological · Drug
- Lead sponsor
- R-Pharm Overseas, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Richmond, Virginia
- Conditions
- Covid19
- Interventions
- Remdesivir, Remdesivir Placebo, Aviptadil, Aviptadil Placebo, Corticosteroid
- Biological · Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 473 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 40
- States / cities
- Tucson, Arizona • Fresno, California • Loma Linda, California + 28 more
- Conditions
- Variola Major (Smallpox)
- Interventions
- Placebo, MVA-BN
- Drug · Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2012
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Bronchopulmonary Dysplasia, Respiratory Distress Syndrome, Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature
- Interventions
- Minimal mechanical ventilation management, Routine mechanical ventilation management, Dexamethasone, Placebo
- Procedure · Drug
- Lead sponsor
- NICHD Neonatal Research Network
- Network
- Eligibility
- 5 Minutes to 10 Days
- Enrollment
- 220 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2002
- U.S. locations
- 13
- States / cities
- Birmingham, Alabama • Palo Alto, California • New Haven, Connecticut + 10 more
- Conditions
- Knee Osteoarthritis
- Interventions
- NANOVAE - Acellular Allogenic Human Amniotic Fluid (hAF), 0.9% Sodium Chloride Injection, USP
- Drug
- Lead sponsor
- Nova Vita Laboratory
- Industry
- Eligibility
- 21 Years to 75 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Chesterfield, Missouri
- Conditions
- Shivering, Nausea and Vomiting, Postoperative
- Interventions
- Dexmedetomidine, Placebo
- Drug
- Lead sponsor
- Beth Israel Deaconess Medical Center
- Other
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Colorectal Disease
- Interventions
- bupivacaine, normal saline placebo (for bupivacaine)
- Drug
- Lead sponsor
- University Hospitals Cleveland Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 79 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Non-Hodgkin Lymphoma, Relapsed/Refractory Diffuse Large B-cell Lymphoma
- Interventions
- NKTR-255 at 1.5 µg/kg, NKTR-255 at 3.0 μg/kg, NKTR-255 at 3.0/6.0 μg/kg, Placebo Comparator
- Drug · Other
- Lead sponsor
- Nektar Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 22
- States / cities
- La Jolla, California • Jacksonville, Florida • Atlanta, Georgia + 17 more
- Conditions
- Genital Herpes Simplex Type 2
- Interventions
- GEN-003 Vaccine (30μg of each antigen), GEN-003 Vaccine (60μg of each antigen), Matrix-M2 Adjuvant (25μg), Matrix-M2 Adjuvant (50μg), Matrix-M2 Adjuvant (75μg), Placebo
- Biological
- Lead sponsor
- Genocea Biosciences, Inc.
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 310 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 16
- States / cities
- Birmingham, Alabama • San Diego, California • San Francisco, California + 12 more
- Conditions
- Staphylococcus (S.) Aureus Infection
- Interventions
- LTB-SA7, Placebo
- Biological
- Lead sponsor
- LimmaTech Biologics AG
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 129 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Graft vs. Host Disease
- Interventions
- Ustekinumab, Placebo, Tacrolimus (TAC), Sirolimus
- Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Atherosclerotic Cardiovascular Disease
- Interventions
- Inclisiran, Placebo
- Drug
- Lead sponsor
- University of Oxford
- Other
- Eligibility
- 40 Years and older
- Enrollment
- 16,124 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2049
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Migraine
- Interventions
- Saline, lidocaine/bupivacaine
- Drug · Combination Product
- Lead sponsor
- Thomas Jefferson University
- Other
- Eligibility
- 18 Years to 80 Years
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Post-stroke Spasticity of the Upper Limb
- Interventions
- IncobotulinumtoxinA (400 Units), Placebo Comparator
- Drug
- Lead sponsor
- Merz Pharmaceuticals GmbH
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 317 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 13
- States / cities
- Downey, California • Fountain Valley, California • Miami, Florida + 10 more
- Conditions
- Herpes Zoster
- Interventions
- mRNA-1468, Placebo, Shingrix
- Biological
- Lead sponsor
- ModernaTX, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 659 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2025
- U.S. locations
- 19
- States / cities
- Los Angeles, California • Longmont, Colorado • Lakeland, Florida + 16 more
- Conditions
- Hip Fracture
- Interventions
- tranexamic acid, placebo
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 138 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Chemotherapy-induced Neuropathic Pain, Chemotherapy-induced Peripheral Neuropathy
- Interventions
- Tetrodotoxin, Placebo
- Drug
- Lead sponsor
- Wex Pharmaceuticals Inc.
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 15
- States / cities
- Santa Ana, California • Santa Rosa, California • Port Charlotte, Florida + 11 more
- Conditions
- Alcohol Withdrawal
- Interventions
- 10 mg/kg IV phenobarbital in 100 ml saline, placebo
- Drug
- Lead sponsor
- Jonathan Rosenson
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 102 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- Oakland, California